Theratechnologies appoints new ceo
John-Michel Huss has more than 20 years’ experience in the pharmaceutical industry
Until recently, Huss was chief of staff, in the office of the ceo, at Sanofi-Aventis in Paris. He has more than 20 years’ experience in the pharmaceutical industry in various international positions and was responsible for various disease areas including diabetes and metabolism.
Huss began his career in 1990, at Merck & Co, primarily in sales and marketing in the US, Germany and Switzerland. In 1996, he was offered a position with F. Hoffman-La Roche as an internal product manager at its Basel headquarters in Switzerland. From there in 1999, he joined Sanofi-Synthélabo as business unit director and has held various positions of increasing responsibility in marketing and sales. He became general manager in Switzerland in 2007.
During his tenure at Sanofi-Aventis (Sanofi-Synthélabo merged with Aventis in 2004) Huss held positions in Germany, Canada, Switzerland and France.
‘I am honoured to have been chosen as Theratechnologies' president and ceo,’ said Huss.
‘The company has done an outstanding job of developing an exciting new compound, tesamorelin, and navigating it through the final regulatory stages of the drug development process.’
You may also like
Research & Development
Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs
Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments
